NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K Filing
NeOnc reported Q1 2026 financial results with a net loss of $8.8 million or $(0.38) per diluted share, compared to $32.3 million or $(1.78) per diluted share in Q1 2025. The company completed the Phase 1 dose-escalation portion of its NEO212 trial and set a recommended Phase 2 dose at 610 mg; it plans to request an FDA End-of-Phase 1 meeting for guidance on potential pivotal trials. NeOnc also secured $10 million in PIPE financing, led by Cinctive Capital, bringing cash reserves to $138,601 as of March 31, 2026. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $NTHI